NRXS

8-K - Neuraxis, INC (0001933567) (Filer)

CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced four additional health insurers with medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 1.25 million covered lives. These medical policies expand incremental access to IB-Stim treatment for beneficiaries in West Virginia, New Hampshire, South Carolina, Virginia, and Florida. "Momentum in expanding insurance coverage for IB-Stim remains strong as we work to make this therapy m

8-K - Neuraxis, INC (0001933567) (Filer)

424B5 - Neuraxis, INC (0001933567) (Filer)

CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that on April 10, 2026, its Board of Directors declared a dividend on its Series B Preferred Stock. Holders of record of the Company's Series B Preferred Stock (the "Series B Preferred Stock") as of the close of business on April 21, 2026 will receive a stock dividend of the Company's common stock, par value $0.001 per share (the "Common Stock"), for every one share of Series B Preferred Stock held. The number of shares of Common Stoc

4 - Neuraxis, INC (0001933567) (Issuer)

4 - Neuraxis, INC (0001933567) (Issuer)

4 - Neuraxis, INC (0001933567) (Issuer)

CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q25.Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth.  Cash balance was $5.0 million as of December 31, 2025. FY2025 Financial Highlights

10-K - Neuraxis, INC (0001933567) (Filer)

CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2025, for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open. The Company has scheduled a conference call for the same day, Thursday, March 19, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Thursday, March 19, 2026, at 9:00am ET Live Webcast Information: Interested parties can access the confere

4 - Neuraxis, INC (0001933567) (Issuer)

4 - Neuraxis, INC (0001933567) (Issuer)

4 - Neuraxis, INC (0001933567) (Issuer)

4 - Neuraxis, INC (0001933567) (Issuer)

4 - Neuraxis, INC (0001933567) (Issuer)

4 - Neuraxis, INC (0001933567) (Issuer)

4 - Neuraxis, INC (0001933567) (Issuer)

SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)

4 - Neuraxis, INC (0001933567) (Issuer)

4 - Neuraxis, INC (0001933567) (Issuer)

The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is now a path to consistent reporting and reimbursement for providers in the medical community. CARMEL, Ind., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now

4 - Neuraxis, INC (0001933567) (Issuer)

CARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation ("PENFS"). The coverage spans multiple states and represents approximately 45 million health plan members. NeurAxis' proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (FD) including associ

CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that it has been awarded a Veterans Affairs (VA) Federal Supply Schedule (FSS) contract, effective December 1, 2025. The first product listed on the FSS is the IB-Stim®, a drug-free treatment for functional abdominal pain in patients 8 years and older. This contract award establishes NeurAxis as a federal contractor and creates a clear commercial pathway into the VA health system, which serves nearly 7 million active patients annually. T